Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.

2.

Pathways leading to an immunological disease: systemic lupus erythematosus.

Zharkova O, Celhar T, Cravens PD, Satterthwaite AB, Fairhurst AM, Davis LS.

Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i55-i66. doi: 10.1093/rheumatology/kew427. Review.

3.

IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation.

Cravens PD, Hussain RZ, Miller-Little WA, Ben LH, Segal BM, Herndon E, Stüve O.

PLoS One. 2016 Oct 25;11(10):e0165248. doi: 10.1371/journal.pone.0165248. eCollection 2016.

4.

Behavioural and neurological symptoms accompanied by cellular neuroinflammation in IL-10-deficient mice infected with Plasmodium chabaudi.

Wilson KD, Stutz SJ, Ochoa LF, Valbuena GA, Cravens PD, Dineley KT, Vargas G, Stephens R.

Malar J. 2016 Aug 24;15(1):428. doi: 10.1186/s12936-016-1477-1.

5.

The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis.

Cravens PD, Kieseier BC, Hussain R, Herndon E, Arellano B, Ben LH, Timmons BC, Castro-Rojas C, Hartung HP, Hemmer B, Weber MS, Zamvil SS, Stüve O.

J Neuroinflammation. 2013 May 24;10:67. doi: 10.1186/1742-2094-10-67.

6.

Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity.

Hertzenberg D, Lehmann-Horn K, Kinzel S, Husterer V, Cravens PD, Kieseier BC, Hemmer B, Brück W, Zamvil SS, Stüve O, Weber MS.

Eur J Immunol. 2013 Aug;43(8):2078-88. doi: 10.1002/eji.201343338. Epub 2013 Jun 3.

7.

CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke.

Stowe AM, Wacker BK, Cravens PD, Perfater JL, Li MK, Hu R, Freie AB, Stüve O, Gidday JM.

J Neuroinflammation. 2012 Feb 16;9:33. doi: 10.1186/1742-2094-9-33.

8.

Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet.

Cravens PD, Hussain RZ, Zacharias TE, Ben LH, Herndon E, Vinnakota R, Lambracht-Washington D, Nessler S, Zamvil SS, Eagar TN, Stüve O.

J Neuroinflammation. 2011 Jun 24;8:73. doi: 10.1186/1742-2094-8-73.

9.

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NL.

Eur J Immunol. 2010 Oct;40(10):2942-56. doi: 10.1002/eji.201040516.

10.

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O.

Arch Neurol. 2010 Aug;67(8):923-30. doi: 10.1001/archneurol.2010.161. Review.

11.

Silencing Nogo-A promotes functional recovery in demyelinating disease.

Yang Y, Liu Y, Wei P, Peng H, Winger R, Hussain RZ, Ben LH, Cravens PD, Gocke AR, Puttaparthi K, Racke MK, McTigue DM, Lovett-Racke AE.

Ann Neurol. 2010 Apr;67(4):498-507. doi: 10.1002/ana.21935.

12.

Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling.

Hu W, Nessler S, Hemmer B, Eagar TN, Kane LP, Leliveld SR, Müller-Schiffmann A, Gocke AR, Lovett-Racke A, Ben LH, Hussain RZ, Breil A, Elliott JL, Puttaparthi K, Cravens PD, Singh MP, Petsch B, Stitz L, Racke MK, Korth C, Stüve O.

Brain. 2010 Feb;133(Pt 2):375-88. doi: 10.1093/brain/awp298. Epub 2010 Feb 9.

13.

Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.

Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, Stüve O.

Arch Neurol. 2009 Aug;66(8):1016-20. doi: 10.1001/archneurol.2009.157. Erratum in: Arch Neurol. 2009 Nov;66(11):1384.

PMID:
19667224
14.

T-bet is essential for encephalitogenicity of both Th1 and Th17 cells.

Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, Peng H, Cravens PD, Racke MK, Lovett-Racke AE.

J Exp Med. 2009 Jul 6;206(7):1549-64. doi: 10.1084/jem.20082584. Epub 2009 Jun 22.

15.

PEG minocycline-liposomes ameliorate CNS autoimmune disease.

Hu W, Metselaar J, Ben LH, Cravens PD, Singh MP, Frohman EM, Eagar TN, Racke MK, Kieseier BC, Stüve O.

PLoS One. 2009;4(1):e4151. doi: 10.1371/journal.pone.0004151. Epub 2009 Jan 7.

16.

Quinpramine is a novel compound effective in ameliorating brain autoimmune disease.

Singh MP, Meyer zu Hörste G, Hu W, Mausberg AK, Cravens PD, Eagar T, Löber S, Klingenstein R, Gmeiner P, Korth C, Kieseier BC, Stüve O.

Exp Neurol. 2009 Feb;215(2):397-400. doi: 10.1016/j.expneurol.2008.10.001. Epub 2008 Oct 21.

PMID:
18996373
17.

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.

Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radü EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK.

Neurology. 2009 Feb 3;72(5):396-401. doi: 10.1212/01.wnl.0000327341.89587.76. Epub 2008 Nov 5.

18.

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O.

Arch Neurol. 2008 Dec;65(12):1596-603. doi: 10.1001/archneur.65.12.noc80051. Epub 2008 Oct 13.

PMID:
18852339
19.

DNA-based vaccines: the future of multiple sclerosis therapy?

Stüve O, Cravens PD, Eagar TN.

Expert Rev Neurother. 2008 Mar;8(3):351-60. doi: 10.1586/14737175.8.3.351. Review.

PMID:
18345967
20.

DNA plasmid vaccination for multiple sclerosis.

Stüve O, Eagar TN, Frohman EM, Cravens PD.

Arch Neurol. 2007 Oct;64(10):1385-6. No abstract available.

PMID:
17923622
21.

High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes.

Stüve O, Cravens PD, Singh MP, Frohman EM, Phillips JT, Remington G, Hu W, Hemmer B, Olek MJ, Monson NL, Racke MK.

Arch Neurol. 2007 Jul;64(7):1055-6. No abstract available.

PMID:
17620501
22.
23.

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.

Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.

Arch Neurol. 2007 Feb;64(2):169-76. Review.

PMID:
17296831
24.

T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity.

Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, Racke MK, Lovett-Racke AE.

J Immunol. 2007 Feb 1;178(3):1341-8.

25.

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.

Arch Neurol. 2006 Oct;63(10):1383-7.

PMID:
17030653
26.

Immune surveillance in multiple sclerosis patients treated with natalizumab.

Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK.

Ann Neurol. 2006 May;59(5):743-7.

PMID:
16634029
27.

Therapeutic potential of small interfering RNA for central nervous system diseases.

Lovett-Racke AE, Cravens PD, Gocke AR, Racke MK, Stüve O.

Arch Neurol. 2005 Dec;62(12):1810-3. Review. No abstract available.

PMID:
16344338
28.

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.

Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK.

Arch Neurol. 2005 Feb;62(2):258-64.

PMID:
15710854
29.

Development and activation of human dendritic cells in vivo in a xenograft model of human hematopoiesis.

Cravens PD, Melkus MW, Padgett-Thomas A, Islas-Ohlmayer M, Del P Martin M, Garcia JV.

Stem Cells. 2005 Feb;23(2):264-78.

30.

Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.

Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin Mdel P, Netto G, Garcia JV.

J Virol. 2004 Dec;78(24):13891-900.

31.

Dendritic cells, chemokine receptors and autoimmune inflammatory diseases.

Cravens PD, Lipsky PE.

Immunol Cell Biol. 2002 Oct;80(5):497-505. Review.

PMID:
12225387

Supplemental Content

Loading ...
Support Center